The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


About Asieris Pharma

Asieris Pharma (688176.SH) is a Chinese company focused on developing cancer treatment technology. The company is developing a repurposed oral inhibitor of MetAP2, a spectrum antibiotic that has been shown to have an anti-angiogenesis effect. It will be tested as a treatment for patients with relapsed non-muscle invasive bladder cancer (NMIBC).

Asieris Pharma Headquarter Location

12F, Building 56, Kinling Zhidu, No. 1000, Jinhai Rd. Pudong New Area

Shanghai, Shanghai, 225300,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Asieris Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Asieris Pharma is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Asieris Pharma Patents

Asieris Pharma has filed 3 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Antidepressants
  • Antineoplastic drugs
patents chart

Application Date

Grant Date


Related Topics




Antineoplastic drugs, Experimental cancer drugs, Cancer treatments, Immunology, Antiseptics


Application Date


Grant Date



Related Topics

Antineoplastic drugs, Experimental cancer drugs, Cancer treatments, Immunology, Antiseptics



Latest Asieris Pharma News

Week in Review: Week's China Life Science Deals Total Over $2.5 Billion

Jun 19, 2021

publication date: Jun 19, 2021  |  Shanghai 's Zai Lab (NSDQ: ZLAB; HK: 9688) announced a four-drug immunonocology deal with MacroGenics (NSDQ: MGNX) worth over $1.4 billion (see story ). Both companies will contribute IP to the products. Zai Lab will have Asian and/or global rights for up to four CD3- or CD47-based bispecific molecules from Macrogenics, plus Zai will have rights to MacroGenics' DART® and TRIDENT® multi-specific platforms. In return, Zai will provide MacroGenics with rights to specific CD47 IP for select tumor targets. Zai will make an upfront payment of $25 million and an investment of $30 million in MacroGenics, plus up to $1.4 billion in milestone payments. Shanghai 's HutchMed (formerly Hutchison Chi-Med) (NSDQ/AIM: HCM is planning to raise $600 million in a Hong Kong IPO (see story ). HutchMed has launched two novel oncology drugs in  China , and it has eight more candidates in development. The Hong Kong IPO is the third listing for the company, following its first on  London US . The company has a $4.3 billion market cap on NASDAQ. Cornerstone investors have agreed to purchase $325 million (54%) of the offered shares. HutchMed will set the purchase price on June 23. Beijing 's LinkDoc Technology, an AI driven healthcare company based on cancer patient data, filed to IPO on the NASDAQ exchange (see story ). LinkDoc has been supported by Alibaba. The company structures cancer patient data, which it acquires from 330 top tier  China  hospitals, to support precision medicine and personalized care. So far, it has longitudinal data on 2.5 million oncology patients and has helped 3.5 million patients. During its most recent 12 months, LinkDoc booked $157 million in revenue and claims to have the largest  China  market share in its field. LinkDoc may be seeking to raise as much as $500 million. HiFiBiO, a US-China biotech, closed a $75 million Series D financing to support clinical trials of its two leading antibody therapies for oncology (see story ). HiFiBiO uses its proprietary single-B-cell functional antibody discovery platform, CelliGO™, to discover candidates. In addition to developing its own drugs, the company has formed several strategic discovery partnerships with pharmas and biotechs. The D round was led by new investor Mirae Asset, a global company. HiFiBiO is headquartered in  Cambridge Shanghai  gene-editing company, closed a $62 million Series B round for its gene editing tools and drug discovery programs based on gene editing for rare diseases (see story ). Founded in 2018, HuiGene says it focuses on the CRISPER-Cas editing system, based on the Cas19 protein and targeting ssRNA to edit RNA. Because this technology does not change DNA, the company says it offers better safety than competing gene editing programs. It is carrying out R&D of gene therapies for neurodegenerative diseases, visual disorders, hearing disorders and other diseases. OncoNano Medicine, located in a suburb of  Dallas Texas , raised $50 million for its novel pH-based cancer products in a B round led by Advantech Capital, a  China  cross border investor (see story ). Proceeds of the round will be used to support the Phase II US/EU clinical trials for pegsitacianine, a real-time imaging agent used in intraoperative surgical resection of solid tumors, and to accelerate development of ONM-501, a novel immunoncology molecule. OncoNano was founded by Jinming Gao, PhD, who received his BS from  Peking Trials and Approvals  Suzhou Innovent Bio (HK: 01801) has dosed the first person in a China Phase II trial of  a dual agonist treatment for obesity (see story ). IBI362 is a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) that features once-weekly dosing. Innovent acquired  China  rights to the candidate from Lilly (NYSE: LLY), its global partner. In 2015, the two companies signed a $1 billion deal for Innovent's PD-1 along with a two-way partnership of other assets. The trial will evaluate the change from baseline body weight at week 24. ImmVira of Shenzhen has dosed the first patients in a China/US Phase II trial of its lead drug, an oncolytic virus product (see story ). MVR-T3011 is a proprietary next-gen, genetically modified oncolytic herpes simplex virus (oHSV) delivered to the tumor. It was developed on a novel virus backbone design that was driven by ImmVira's insights into oncolytic viruses and recombinant gene expertise. In its Phase I trials, MVR-T3011 showed promising safety and efficacy. It will be tested in solid tumors and melanoma. Sirnaomics, a Maryland-Suzhou RNAi company, will add a China Phase IIb trial for its lead drug to the  US  trial, already underway (see story ). The company will test STP705, a siRNA (small interfering RNA) candidate that inhibits TGF-β1 and COX-2 gene expression in patients with skin squamous cell carcinoma (in situ). Sirnaomics uses its polypeptide nanoparticle (PNP)-enhanced technology to deliver the drug. The trial will enroll 100 adult patients with isSCC in five to seven clinical sites in the  US . STP705 is also approved for testing in cholangiocarcinoma, non-melanoma skin cancer and hypertrophic scar. Beijing Jacobio Pharma (HK: 1167) has dosed the first two patients in a Phase I/IIa trial of its SHP2 inhibitor in patients with solid tumor cancers (see story ). One year ago, Jacobio out-licensed global rights for two small molecule SHP2 inhibitors to AbbVie (NYSE: ABBV). AbbVie made a $45 million upfront payment to Jacobio, and the start of the trial triggers a $20 million milestone payment from AbbVie. The SHP2 inhibitor, JAB-3312, will be administered in combination with PD-1 antibody pembrolizumab and MEK inhibitor binimetinib. Asieris Pharma of  Shanghai  has been approved to start US trials of its MetAP2 inhibitor in patients with muscle invasive bladder cancer (MIBC) (see story ). APL-1202 is an oral reversible MetAP2 inhibitor with anti-angiogenic, anti-tumor activities that is also believed to modulate the tumor immune microenvironment. The MetAP2 inhibitor will be administered along with BeiGene's approved anti-PD-1 drug, tislelizumab. Asieris plans to accelerate patient enrollment in the  US

Asieris Pharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Asieris Pharma Rank

  • When was Asieris Pharma founded?

    Asieris Pharma was founded in 2013.

  • Where is Asieris Pharma's headquarters?

    Asieris Pharma's headquarters is located at 12F, Building 56, Kinling Zhidu, No. 1000, Jinhai Rd., Shanghai.

  • What is Asieris Pharma's latest funding round?

    Asieris Pharma's latest funding round is IPO.

  • How much did Asieris Pharma raise?

    Asieris Pharma raised a total of $175.66M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.